Li Li, director of the China Drug Administration, said in an interview that the drug regulatory authorities will adhere to the combination of an effective market and a promising government, respect the dominant position of pharmaceutical companies in innovation, support enterprises to strengthen the research and release of innovative pharmaceutical devices, and help enterprises transform new pharmaceutical technology into new quality productivity. Deepen and expand pilot reform results such as clinical trial review and approval, supplementary application review and approval procedures, and segmented production, and implement “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, and fully tilt review resources towards “new global” original products and domestic alternative products that break through “stuck neck” technology to help the high-quality development of the pharmaceutical industry through the optimization of regulatory policies. Accelerate the promotion of participation in international drug testing cooperation programs, initiate evaluations of agencies applying for listing by the World Health Organization, support export trade in pharmaceuticals, medical devices, and cosmetics, and support the pharmaceutical industry to open up cooperation with the outside world.

Li Li, director of the China Drug Administration, said in an interview that the drug regulatory authorities will adhere to the combination of an effective market and a promising government, respect the dominant position of pharmaceutical companies in innovation, support enterprises to strengthen the research and release of innovative pharmaceutical devices, and help enterprises transform new pharmaceutical technology into new quality productivity. Deepen and expand pilot reform results such as clinical trial review and approval, supplementary application review and approval procedures, and segmented production, and implement “early intervention, one enterprise, one policy, full guidance, research and review linkage” for key varieties, and fully tilt review resources towards “new global” original products and domestic alternative products that break through “stuck neck” technology to help the high-quality development of the pharmaceutical industry through the optimization of regulatory policies. Accelerate the promotion of participation in international drug testing cooperation programs, initiate evaluations of agencies applying for listing by the World Health Organization, support export trade in pharmaceuticals, medical devices, and cosmetics, and support the pharmaceutical industry to open up cooperation with the outside world.